Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.36
Nov 20 • 3:59 PM ET Dollar change-0.02 Percentage change(-1.81%)
Aftermarket Close
1.38
Aftermarket • 7:30 PM ET Dollar change+0.02 Percentage change(1.47%)
Index
-
Market Cap
75.91M
Enterprise Value
-58.25M
Income
-63.47M
Sales
13.95M
Book/sh
3.81
Cash/sh
2.79
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
124
IPO
Dec 04, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
5.44
P/B
0.36
P/C
0.49
P/FCF
-
EV/EBITDA
-
EV/Sales
-4.18
Quick Ratio
16.24
Current Ratio
16.89
Debt/Eq
0.10
LT Debt/Eq
0.09
Option/Short
Yes / Yes
EPS (ttm)
-1.14
EPS next Y
-0.96
EPS next Q
-0.22
EPS this Y
15.52%
EPS next Y
11.55%
EPS next 5Y
15.04%
EPS past 3/5Y
4.89% -18.95%
Sales past 3/5Y
3.15% 89.71%
EPS Y/Y TTM
16.31%
Sales Y/Y TTM
-14.56%
EPS Q/Q
23.63%
Sales Q/Q
-3.40%
Insider Own
33.39%
Insider Trans
-0.15%
Inst Own
30.08%
Inst Trans
6.32%
ROA
-23.06%
ROE
-26.19%
ROIC
-27.37%
Gross Margin
46.04%
Oper. Margin
-475.14%
Profit Margin
-455.00%
SMA20
-17.79%
SMA50
-27.82%
SMA200
-28.38%
Trades
Shs Outstand
55.81M
Shs Float
37.18M
52W High
2.38 -42.74%
52W Low
1.36 0.00%
Volatility
8.63% 7.13%
ATR (14)
0.11
RSI (14)
19.38
Beta
1.48
Rel Volume
0.60
Avg Volume
215.69K
Volume
130,288
Perf Week
-13.38%
Perf Month
-30.96%
Perf Quarter
-33.33%
Perf Half Y
-24.02%
Perf YTD
-25.68%
Perf Year
-29.90%
Perf 3Y
-22.29%
Perf 5Y
-94.62%
Perf 10Y
-
Prev Close
1.38
Price
1.36
Change %
-1.81%
Consensus
Strong Buy
Avg. Price Target
$4.00
Implied Upside
+194.1%
Analysts5incl. previous ratings
Rating Distribution2 Buy · 2 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 04, 2026Initiated
CCanaccord Genuity
Buy$4+194.1%
Jul 05, 2023Resumed
JPM logoJJP Morgan
Neutral$10+635.3%
Jan 04, 2023Downgrade
BAC logoBBofA Securities
Neutral → Underperform$9 → $6.50+377.9%
Aug 11, 2022Downgrade
JPM logoJJP Morgan
Overweight → Neutral$20 → $12+782.4%
Oct 15, 2021Resumed
CCowen
Outperform
Dec 29, 2020Initiated
MS logoMMorgan Stanley
Equal-Weight$65+4,679.4%
Dec 29, 2020Initiated
JPM logoJJP Morgan
Overweight$75+5,414.7%
Dec 29, 2020Initiated
CCowen
Outperform
Dec 29, 2020Initiated
BAC logoBBofA Securities
Neutral$69+4,973.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Endweiss CharlesVP Financial Planning AnalysisNov 18 '26Sale1.462,4473,578140,194Nov 19 06:58 PM
Horn David R.PRESIDENT & CFOAug 18 '26Sale2.037,30914,809486,650Aug 19 06:59 PM
Nishar DipchandDirectorJul 08 '26Sale2.1810,66023,26559,044Jul 10 06:23 PM
DIPCHAND NISHARDirectorJul 08 '26Proposed Sale2.1810,66023,265Jul 08 04:03 PM
Horn David R.PRESIDENT & CFOMay 20 '26Sale1.697,30312,352493,959May 21 05:12 PM
Horn David R.PRESIDENT & CFOFeb 18 '26Sale1.997,74315,447501,262Feb 19 04:11 PM
Farokhzad OmidCEO AND CHAIRFeb 18 '26Sale1.9924,38548,6463,349,064Feb 19 04:06 PM
Seer, Inc. engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite consists of automation instruments and software, which provide a workflow to make proteomic profiling. The company was founded by Philip Ma, Robert S. Langer Jr. and Omid C. Farokhzad on March 16, 2017 and is headquartered in Redwood City, CA.
Ph.D.Dr. Omid C. Farokhzad M.D.
Chief Operations & Product OfficerKenny Ross
Chief People OfficerMs. Marissa Dixon
Senior Vice President of Product DevelopmentMr. Martin Goldberg Ph.D.
Senior Vice President of Research & Tech DevelopmentDr. Asim Siddiqui Ph.D.